Increasing cases of complex diseases such as cancer & other cardiovascular diseases may require the research process for protein expression & it could be a vital driver in the growth of the eukaryotic expression systems market. Increasing research & development for therapeutics for such diseases would result in the advancement of the eukaryotic expression system, hence favoring the growth of the market. Protein expression forms an integral part of proteomic research which is in the high growth phase. The decline in productivity of research & development in pharmaceuticals, increasing intensity of research, the rise of the biologics market, sales drop resulting from upcoming patient cliffs is other crucial drivers for this market. The protein expression system is segmented into the eukaryotic expression system & prokaryotic expression system.
The market for eukaryotic expression systems has been divided into four segments globally which are products, applications, end-users, host types. Host types market is sub-segmented into S.cerevisiae, Filamentous fungi, Leishmania, Baculovirus infected cells. The market for eukaryotic expression system includes reagents, expression vectors & competent cells which may be used in the process of transfection. The eukaryotic expression system is an artificial system that includes drug development & manufacturing of recombinant proteins, these are then used as research tools & therapeutics. Eukaryotic expression systems types include MEL, COS, CHO & insect cells. Eukaryotic hosts are as easy to handle as E.coli. They possess stable expression strains for constant protein production.
There is an increasing trend for the pharmaceutical companies that are outsourcing the research activities to contract research organizations, companies that have unmet manpower & expertise, infant research labs. So, the service sector of the protein expression market is bound to grow. The eukaryotic expression system market is globally classified in North America, Europe, Asia Pacific & RoW. North America is expected to hold the maximum market share in this market. The developing economies in the Middle East & Asia Pacific are expected to have a relevant growth in this eukaryotic expression systems market owing to huge untapped potential & increased expenditure in research & development. Key players of this eukaryotic expression system market include Thermo Fisher Scientific, Life Technologies Corporation, Jena Biosciences, New England Biolabs, Takara Bio Inc., Bio-Rad Technologies, Promega Corporation, Agilent Technologies, Merck Millipore, Sigma Aldrich Corporation & Qiagen.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.